10-K: Oramed Pharmaceuticals Amends Consulting and Employment Agreements, Files Annual Report

Oramed Pharmaceuticals has amended consulting and employment agreements with key personnel and filed its annual report, detailing financial results and strategic updates.

Summary

• Oramed Pharmaceuticals has amended its consulting agreement with Shnida Ltd., effective January 1, 2024, increasing the monthly payment to NIS 96,825.
• The company also amended its employment agreement with Nadav Kidron, effective January 1, 2024, setting his gross monthly salary at NIS 51,591.
• Oramed's annual report for the fiscal year ended December 31, 2023, shows a net income of $5.1 million, a significant turnaround from a net loss of $37.8 million in 2022.
• The company's revenue decreased by 50% to $1.34 million in 2023, compared to $2.7 million in 2022.
• Research and development expenses decreased by 68% to $9 million in 2023, compared to $27.6 million in 2022.
• The company completed an analysis of the ORA-D-013-1 Phase 3 trial data, identifying subpopulations that responded well to oral insulin, and is working on a new Phase 3 trial protocol.
• Oramed entered into a Joint Venture Agreement with HTIT Biotech to develop and commercialize products based on Oramed's oral drug delivery technology.
• The company received a $5 million principal payment from Scilex on December 21, 2023, as part of a $101.9 million senior secured promissory note.
• Oramed's strategic review process is ongoing, with the goal of enhancing value for stockholders.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company achieved a net income and reduced expenses, the revenue decline and strategic uncertainty temper the positive aspects. The ongoing strategic review and potential need for additional funding add to the uncertainty.

Positives

• Oramed achieved a net income of $5.1 million in 2023, a substantial improvement from the previous year's loss.
• The company significantly reduced its research and development expenses by 68% in 2023.
• The analysis of the ORA-D-013-1 Phase 3 trial data identified patient subpopulations that responded well to oral insulin, providing a path forward for the technology.
• The joint venture with HTIT Biotech provides a potential avenue for commercialization and further development of Oramed's technology.
• The receipt of a $5 million principal payment from Scilex strengthens the company's financial position.

Negatives

• Oramed's revenue decreased by 50% in 2023 compared to 2022.
• The company's strategic review process indicates uncertainty about its future direction.
• The company has a history of losses and may not achieve profitability in the near future.
• The company is dependent on third-party suppliers for raw materials and services.
• The company is exposed to fluctuations in currency exchange rates.

Risks

• The strategic review process may not be successful or timely, potentially impacting the company's future.
• The company may not be able to obtain additional funding on acceptable terms.
• Clinical trials may encounter delays, suspensions, or other problems.
• The company may not be able to realize the full value of the warrants received from Scilex.
• The company is affected by the political, economic, and military risks of having operations in Israel.
• The company is exposed to fluctuations in currency exchange rates.
• The company is dependent on third party suppliers of raw materials and for other services.

Future Outlook

Oramed is working on a new Phase 3 clinical trial protocol and evaluating strategic opportunities to enhance stockholder value. The company believes it can maintain current activities for at least the next 12 months, but may need additional funding.

Management Comments

• Management believes that it will be able to secure the necessary financing as a result of future third party investments.
• Management continues to evaluate various financing alternatives for funding new strategic activities, future research and development activities and general and administrative expenses through fundraising in the public or private equity markets.

Industry Context

The document reflects the challenges and strategic shifts faced by pharmaceutical companies in the development of new therapies, particularly in the diabetes space. The focus on strategic partnerships and financial restructuring is a common theme in the industry.

Comparison to Industry Standards

• The decrease in R&D spending is significant and may be compared to other biotech companies that have faced setbacks in clinical trials, such as Lexicon Pharmaceuticals which reduced its R&D spending after a failed phase 3 trial.
• The joint venture with HTIT Biotech is similar to other partnerships in the pharmaceutical industry, such as the collaboration between Eli Lilly and Innovent Biologics, which aim to leverage each other's strengths in development and commercialization.
• The financial restructuring involving the Scilex note and warrants is similar to other biotech companies that have used debt financing and equity instruments to manage their capital structure, such as Sorrento Therapeutics which has also used debt financing and equity instruments to manage its capital structure.
• The company's focus on identifying subpopulations that respond well to oral insulin is similar to other companies that are using precision medicine approaches to improve clinical trial outcomes, such as Vertex Pharmaceuticals which has used genetic testing to identify patients who are more likely to respond to its cystic fibrosis drugs.

Management Changes

Corporate Governance

Related Party Transactions

• The company has ongoing consulting agreements with Shnida Ltd. and KNRY Ltd., entities owned by key personnel.
• The company has employment agreements with Nadav Kidron and David Silberman.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the strategic review process and uncertainty about the company's future.
• Employees may be affected by potential changes in the company's strategic direction and any resulting restructuring.
• Customers and partners may be impacted by the company's focus on strategic partnerships and potential changes in product development.

Next Steps

• The company will continue its strategic review process.
• The company will work on a protocol for a new Phase 3 clinical trial to be submitted to the FDA.
• The company will work with HTIT Biotech to establish the joint venture and develop products based on Oramed's technology.

Key Dates

Keywords

Oramed Pharmaceuticals, oral insulin, clinical trials, joint venture, HTIT Biotech, Scilex, financial results, strategic review, drug delivery, biotechnology